$NVO: the DKK150bn ambition still has to become profitable growth

The July 31 ZEUS trial failed to reduce major cardiovascular events, and the ADR fell 8.8% that session. By Friday it was $43.24, below July 31's $47.08. The question hanging over the stock is whether new products can replace growth investors used to expect from semaglutide.

Today's ambition is more than DKK150 billion of risk-adjusted pipeline sales in 2035. That is a revenue ambition, not present value, earnings or financial guidance. The nearer ambition is peer-like revenue growth through 2030 with a broadly stable adjusted operating margin. There is no numerical growth rate in the highlights release.

Novo's US presentation shows first-half adjusted sales down 4% at constant exchange rates while describing strong GLP-1 volume growth. Patient reach can expand while pricing consumes the benefit. Sandoz's September 18 Canadian generic approval makes that competition tangible; Sandoz expects no material 2026 contribution. Our reading is that the stock needs evidence of profitable growth before a distant pipeline ambition can repair confidence.

CagriSema's new phase 3 results strengthen the scientific case. The diabetes comparison used 5 mg tirzepatide; it does not establish superiority across all doses. Approval and commercial returns are still ahead. The test is whether better treatments produce durable revenue and cash after access discounts, manufacturing and development spending. A large patient market alone cannot settle that arithmetic.